

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCHWEIGER ET AL.

Atty. Ref.: 620-431

Serial No. 10/573,882

Group: Unknown

Filed: March 29, 2006

Examiner: Unknown

For: METHODS OF [11C]-RADIOLABELLING
PHENOTHIAZINE AND PHENOTHIAZINE-LIKE
COMPOUNDS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 26, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
 B. J. Sadoff
 Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-431

10/573,882

APPLICANT

SCHWEIGER ET AL.

(Use several sheets if necessary)

FILING DATE

GROUP

March 29, 2006

Unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FLING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
D1	WO 02/075318	09/2002	WIPO		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

D2	Bolton, R., 2001, "Isotopic methylation," <u>J. Labelled Comp. Radiopharm.</u> , Vol. 44, pp. 701-736.
D3	Crouzel, C., et al., 1987, "Recommendations for a practical production of [¹¹ C]methyl iodide," <u>Appl. Radiat. Isot.</u> , Vol. 38, pp. 601-603.
D4	Czernin, J., et al., 2002, "Positron emission tomography scanning: current and future applications," <u>Annual Review of Medicine</u> , Vol. 53, pp. 89-112.
D5	Fowler, J.S., et al., 1999, "PET and drug research and development," <u>Journal of Nuclear Medicine</u> , Vol. 40, No. 7, pp. 1154-1163.
D6	Goh, A.S.W., et al., 2003, "Clinical positron emission tomography imaging - Current applications," <u>Annals Academy of Medicine Singapore</u> , Vol. 32, No. 4, pp. 507-517.
D7	Iwata, R., et al., 2001, "A simple loop method for the automated preparation of [¹¹ C]raclopride from [¹¹ C]methyl triflate," <u>Appl. Radiat. Isot.</u> , Vol. 55, pp. 17-22.
D8	Iwata, R., et al., 2002, "A combined loop-SPE method for the automated preparation of [¹¹ C]doxepin," <u>J. Label. Compd. Radiopharm.</u> , Vol. 45, pp. 271-280.
D9	Jewett, D.M., 1992, "A simple synthesis of [¹¹ C]methyl triflate," <u>Appl. Rad. Isot.</u> , Vol. 43, No. 11, pp. 1383-1385.
D10	Kennedy, S.H., et al., 1997, "A review of functional neuroimaging in mood disorders: positron emission tomography and depression," <u>Canadian Journal of Psychiatry</u> , Vol. 42, No. 5, pp. 467-475.
D11	Link, E.M., et al., 1998, "Early detection of melanoma metastases with radiiodinated methylene blue," <u>Eur. J. Nucl. Med.</u> , Vol. 25, pp. 1322-1329.
D12	Lundkvist, C., et al., 1998, "Improved synthesis of PET radioligands, [¹¹ C]FLB 457, [¹¹ C]MDL and [¹¹ C]β-CIT-FE, by the use of [¹¹ C]methyl triflate," <u>J. Labelled Comp. Radiopharm.</u> , Vol. 41, pp. 545-556.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-FB-A629 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-431

10/573,882

APPLICANT

SCHWEIGER ET AL.

(Use several sheets if necessary)

FILING DATE

GROUP

March 29, 2006

Unknown

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

D13	Nägren, K., et al., 1998, "Methylation of amide and thiol functions with [¹¹ C]methyl triflate, as exemplified by [¹¹ C]NMSP, [¹¹ C]flumazenil and [¹¹ C]methionine," <u>J. Labelled Comp. Radiopharm.</u> , Vol. 41, pp. 831-841.
D14	Nägren, K., et al., 1995, "Improved synthesis of some commonly used PET radioligands by the use of [¹¹ C]methyl triflate," <u>Nucl. Med. Biol.</u> , Vol. 22, No. 2, pp. 235-239.
D15	Potts, A.M., 1964, "The reaction of uveal pigment with polycyclic compounds," <u>Invest. Ophthalmol. Visual. Sci.</u> , Vol. 3, pp. 405-416.
D16	Schweiger, L., et al., 2003, "Radiosynthesis of [N-methyl- ¹¹ C]methylene blue," <u>J. Label. Compd. Radiopharm.</u> , Vol. 46, pp. 1221-1228.
D17	Turner, J.H., et al., 1985, "Localization of ¹¹ C-radiopharmaceuticals in the Greene melanoma of hamsters," <u>Eur. J. Nucl. Med.</u> , Vol. 10, pp. 382-397.
D18	Van Heertum RL, et al., 2003, "Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia," <u>Seminars in Nuclear Medicine</u> , Vol. 33, No. 1, pp. 77-85.
D19	Wischik, C.M., et al., 2000, "Chapter 5: The molecular basis of tau protein pathology in Alzheimer's disease and related neurodegenerative dementias," in <u>Neurobiology of Alzheimer's Disease</u> (editors Dawbarn, D. and Allen, S.J.) in <u>The Molecular and Cellular Neurobiology Series</u> , (Oxford University Press).
D20	International Preliminary Report on Patentability (IPRP) of PCT/GB2004/004153.
D21	International Search Report (ISR) of PCT/GB2004/004153.
D22	Search Report of GB 0322756.8.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-AE29 (Also PTO-1449)